{"entity":{"id":"nct05566795","kind":"trial","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","aka":[],"tldr":"A phase 3 trial of Tovorafenib in glioma & glioblastoma, run by Day One Biopharmaceuticals, Inc., active and no longer recruiting.","summary":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) is a phase 3 interventional study registered as NCT05566795 by Day One Biopharmaceuticals, Inc., with 418 participants enrolled, started 2023-02-27 and due to reach its primary completion in 2027-06. Interventions recorded: Tovorafenib and Chemotherapeutic Agent.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05566795","url":"https://clinicaltrials.gov/study/NCT05566795"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tovorafenib"],"companies":["day-one-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05566795","phase":"3","setting":"LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy","sponsor":"Day One Biopharmaceuticals, Inc.","enrolled":418,"outcomes":[]},"route":"/trials/nct05566795/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"tovorafenib","kind":"drug","name":"Tovorafenib","route":"/drugs/tovorafenib/"}],"company":[{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/"}]}}